ATE448222T1 - 2,4-dioxo-3-chinazolinylarylsulfonylharnstoffe - Google Patents

2,4-dioxo-3-chinazolinylarylsulfonylharnstoffe

Info

Publication number
ATE448222T1
ATE448222T1 AT04789522T AT04789522T ATE448222T1 AT E448222 T1 ATE448222 T1 AT E448222T1 AT 04789522 T AT04789522 T AT 04789522T AT 04789522 T AT04789522 T AT 04789522T AT E448222 T1 ATE448222 T1 AT E448222T1
Authority
AT
Austria
Prior art keywords
sub
sup
group
alkyl
member selected
Prior art date
Application number
AT04789522T
Other languages
German (de)
English (en)
Inventor
Robert Scarborough
Wolin Huang
Anjali Pandey
Shawn Bauer
Xiaoming Zhang
Zhaozhong Jia
Original Assignee
Portola Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc
Application granted granted Critical
Publication of ATE448222T1 publication Critical patent/ATE448222T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
AT04789522T 2003-10-03 2004-09-29 2,4-dioxo-3-chinazolinylarylsulfonylharnstoffe ATE448222T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50856403P 2003-10-03 2003-10-03
PCT/US2004/032921 WO2005032488A2 (en) 2003-10-03 2004-09-29 2,4-dioxo-3-quinazolinylaryl sulfonylureas

Publications (1)

Publication Number Publication Date
ATE448222T1 true ATE448222T1 (de) 2009-11-15

Family

ID=34421757

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04789522T ATE448222T1 (de) 2003-10-03 2004-09-29 2,4-dioxo-3-chinazolinylarylsulfonylharnstoffe

Country Status (15)

Country Link
US (1) US7109332B2 (cg-RX-API-DMAC7.html)
EP (1) EP1668002B1 (cg-RX-API-DMAC7.html)
JP (1) JP2007507551A (cg-RX-API-DMAC7.html)
KR (1) KR20060113700A (cg-RX-API-DMAC7.html)
CN (1) CN1863798B (cg-RX-API-DMAC7.html)
AT (1) ATE448222T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004278030C1 (cg-RX-API-DMAC7.html)
CA (1) CA2540214A1 (cg-RX-API-DMAC7.html)
DE (1) DE602004024093D1 (cg-RX-API-DMAC7.html)
ES (1) ES2334795T3 (cg-RX-API-DMAC7.html)
IL (1) IL174446A (cg-RX-API-DMAC7.html)
MX (1) MXPA06003618A (cg-RX-API-DMAC7.html)
PL (1) PL1668002T3 (cg-RX-API-DMAC7.html)
PT (1) PT1668002E (cg-RX-API-DMAC7.html)
WO (1) WO2005032488A2 (cg-RX-API-DMAC7.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200605587B (en) * 2003-12-22 2008-02-27 Ajinomoto Kk Novel phenylalanine derivative
MX2007003836A (es) * 2004-09-29 2007-08-20 Portola Pharm Inc 2h-1,3-benzoxazin-4(3h)-onas sustituidas.
EA017402B1 (ru) * 2005-11-03 2012-12-28 Портола Фармасьютикалз, Инк. [4-(6-галоген-7-замещенные-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины, их формы, способы получения соединений, фармацевтические композиции, содержащие эти соединения, и их применение
US7834023B2 (en) * 2006-09-20 2010-11-16 Portola Pharmaceuticals, Inc. Substituted dihydroquinazolines as platelet ADP receptor inhibitors
WO2008124532A1 (en) * 2007-04-05 2008-10-16 Cv Therapeutics, Inc. Quinazolinone derivatives as aldh-2 inhibitors
TW200911755A (en) 2007-04-19 2009-03-16 Astellas Pharma Inc Bicyclic heterocyclic compounds
CN101720324A (zh) * 2007-05-02 2010-06-02 波托拉医药品公司 [4-(6-氟-7-甲基氨基-2,4-二氧代-1,4-二氢-2h-喹唑啉-3-基)-苯基]-5-氯-噻吩-2-基-磺酰基脲盐、其相关的形式和方法
CN101654441B (zh) * 2008-08-19 2012-10-03 信谊药厂 抗凝化合物、组合物及其用途
RU2538965C2 (ru) 2009-01-19 2015-01-10 Эббви Инк. Вызывающие апоптоз средства для лечения рака и иммунных и аутоиммунных заболеваний
CA2936120A1 (en) 2009-01-19 2010-07-22 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
ES2586213T3 (es) 2011-10-31 2016-10-13 Xenon Pharmaceuticals Inc. Compuestos de bencenosulfonamida y su uso como agentes terapéuticos
CN104093716B (zh) 2011-10-31 2017-06-23 克赛农制药股份有限公司 联芳醚磺酰胺化合物及其作为治疗剂的用途
HK1209100A1 (en) * 2012-05-22 2016-03-24 基因泰克有限公司 N-substituted benzamides and their use in the treatment of pain
KR101663436B1 (ko) 2012-07-06 2016-10-06 제넨테크, 인크. N-치환된 벤즈아미드 및 이의 사용 방법
KR20150131233A (ko) 2013-03-14 2015-11-24 제넨테크, 인크. 치환된 트리아졸로피리딘 및 이의 사용 방법
WO2014144545A2 (en) 2013-03-15 2014-09-18 Genentech, Inc. Substituted benzoxazoles and methods of use thereof
CN105793238B (zh) 2013-11-27 2019-12-24 基因泰克公司 经取代的苯甲酰胺及其使用方法
EP3166939B1 (en) 2014-07-07 2019-06-05 Genentech, Inc. Therapeutic compounds and methods of use thereof
CN107428696B (zh) 2015-02-16 2021-08-20 昆士兰大学 磺酰脲和相关化合物及其用途
US10179767B2 (en) 2015-05-22 2019-01-15 Genentech, Inc. Substituted benzamides and methods of use thereof
EP3341353A1 (en) 2015-08-27 2018-07-04 Genentech, Inc. Therapeutic compounds and methods of use thereof
EP3356360A1 (en) 2015-09-28 2018-08-08 Genentech, Inc. Therapeutic compounds and methods of use thereof
MA43304A (fr) 2015-11-25 2018-10-03 Genentech Inc Benzamides substitués utiles en tant que bloqueurs de canaux sodiques
EP3436432B1 (en) 2016-03-30 2021-01-27 Genentech, Inc. Substituted benzamides and methods of use thereof
BR112019007763A2 (pt) 2016-10-17 2019-07-02 Genentech Inc composto de fórmula, composição farmacêutica, métodos para tratar uma doença ou condição, para tratar dores, para diminuir o fluxo de íons e para tratar prurido, uso de um composto e invenção
CN110546148A (zh) 2017-03-24 2019-12-06 基因泰克公司 作为钠通道抑制剂的4-哌啶-n-(嘧啶-4-基)色满-7-磺酰胺衍生物
PT3661925T (pt) 2017-07-07 2022-01-31 Inflazome Ltd Novos compostos de sulfonamida-carboxamida
CN111093773A (zh) 2017-08-15 2020-05-01 英夫拉索姆有限公司 作为nlrp3抑制剂的磺酰脲和磺酰硫脲
WO2019034693A1 (en) 2017-08-15 2019-02-21 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
TW201910317A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
US12221434B2 (en) 2017-11-09 2025-02-11 Inflazome Limited Sulfonamide carboxamide compounds
PE20210050A1 (es) 2017-11-09 2021-01-08 Inflazome Ltd Nuevos compuestos de sulfonamida carboxamida
AR114263A1 (es) 2018-02-26 2020-08-12 Genentech Inc Compuestos terapéuticos y métodos para utilizarlos
US11905252B2 (en) 2018-03-02 2024-02-20 Inflazome Limited Compounds
CN111936494A (zh) 2018-03-30 2020-11-13 豪夫迈·罗氏有限公司 作为钠通道抑制剂的取代的氢-吡啶并-吖嗪
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
US20230030720A1 (en) 2018-12-06 2023-02-02 Daiichi Sankyo Company, Limited Cycloalkane-1,3-diamine derivative

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702774D0 (sv) 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
EP1047699A1 (en) 1998-01-15 2000-11-02 Cor Therapeutics, Inc. Platelet adp receptor inhibitors
DE60114994T2 (de) * 2000-02-04 2006-08-03 Portola Pharmaceuticals, Inc., South San Francisco Blutplättchen-adp-rezeptor-inhibitoren
US6906063B2 (en) * 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors

Also Published As

Publication number Publication date
IL174446A0 (en) 2006-08-01
JP2007507551A (ja) 2007-03-29
US20050107357A1 (en) 2005-05-19
AU2004278030B2 (en) 2010-07-01
PT1668002E (pt) 2009-11-25
KR20060113700A (ko) 2006-11-02
CN1863798A (zh) 2006-11-15
WO2005032488A3 (en) 2005-05-12
MXPA06003618A (es) 2006-08-11
EP1668002A4 (en) 2006-12-20
AU2004278030A1 (en) 2005-04-14
IL174446A (en) 2012-02-29
ES2334795T3 (es) 2010-03-16
EP1668002B1 (en) 2009-11-11
CN1863798B (zh) 2011-08-31
US7109332B2 (en) 2006-09-19
HK1093973A1 (en) 2007-03-16
CA2540214A1 (en) 2005-04-14
AU2004278030C1 (en) 2010-12-02
EP1668002A2 (en) 2006-06-14
DE602004024093D1 (de) 2009-12-24
PL1668002T3 (pl) 2010-02-26
WO2005032488A2 (en) 2005-04-14

Similar Documents

Publication Publication Date Title
ATE448222T1 (de) 2,4-dioxo-3-chinazolinylarylsulfonylharnstoffe
ATE449099T1 (de) Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren
MXPA04004457A (es) Novedosos derivados de 1,2,4-tiadiazolio como moduladores del receptor de melanocortina.
BG104248A (en) Benzamidoxim derivatives, intermediate products and methods for preparing and using them as fungicides
GR3034398T3 (en) 2-[1',2',4'-triazol-3'-yloxymethylene]-anilides and their use as pest-control agents
WO2007071632A3 (en) 2-pyridin-2-yl-quinazoline derivatives as potassium channel modulating agents for the treatment of respiratory diseases
WO2004004730A3 (en) 2-aminopyrazine derivatives as inhibitors of cyclin dependent kinases for the treatment of proliferative disorders
EA200401470A1 (ru) Производные пиперазинилацилпиперидина, их получение и их терапевтическое применение
MY146599A (en) New azetidine compounds
AU2003249484A1 (en) Novel bio-active molecules
DK1725536T3 (da) Imidazolin-derivater med CB1-antagonistisk aktivitet
NO20082226L (no) 6-heteroarylpyridoindolonderivater, deres fremstilling og terapeutisk anvendelse derav
HRP20070286T3 (en) Substituted diketopiperazines and their use as oxytocyn antagonists
HRP20050082A2 (en) 6-amino-1h-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors
ATE332695T1 (de) Pyrimidin-derivate als selektive inhibitoren von cox-2
MXPA04003278A (es) Derivados de 5-metoxi-8-aril-?1,2,4?triazolo?1,5-a?piridina como antagonistas del receptor de adenosina.
PT1628968E (pt) Compostos de 4-imidazolin-2-ona
EA200400470A1 (ru) Замещенные производные алкиламинопиридазинона, способ их получения и содержащие их фармацевтические композиции
BR0307424A (pt) Compostos heterocìclicos com atividade inibidora de elastase e seus intermediários
EA200401099A1 (ru) Производные гетероциклического амида
ES2193047T3 (es) (3,4 dihydro-2h-benzo(1,4) oxazinilmetil)(3-(1h-indol-3-il)-alquil)-aminas.
EA200200352A1 (ru) Фенил- и пиридил-тетрагидропиридины, обладающие ингибирующей активностью в отношении фактора некроза опухоли (фно)
AU4932590A (en) Cyclic guanidines uses as calcium antagonists
TW326385B (en) Iminooxybenzyl compounds, their preparation and their use
GB0224306D0 (en) Peripherally-selective inhibitors of dopamine-beta-hydroxylase and method of their preparation

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1668002

Country of ref document: EP